drugset / Trial / NCT06823232

A Study on the Substance Balance of [14C]XY0206 in Healthy Adult Chinese Men

NCT06823232

Phase 1 Completed 6 enrolled Shijiazhuang Yiling Pharmaceutical Co. Ltd
NaSingle-groupOpen-labelOther

Summary

The main purpose of this clinical trial is to quantitatively analyse the total radioactivity in the excreta of subjects after oral administration of \[14C\]XY0206, and to obtain data on human radioactive excretion rate and main excretion routes and the radioactivity of human plasma, urine, and faeces after oral administration of \[14C\]XY0206 by subjects Metabolite profiling, identification of major metabolites, determination of metabolic pathways and elimination pathways; Subjects who met the criteria fasted for at least 10h before administration and took \[14C\]XY0206 suspension (containing about 37.5mg/100µCi\[14C\]XY0206) orally on an empty stomach in the morning of the first day of administration (DI).Subjects will also complete urine, stool and blood collection within a specified period of time。

Timeline

Start
2024-11-06
Primary completion
2024-12-05
Completion
2024-12-05

Drugs

EvaluationDrugModalityDoseRoute
Subject XY0206 Unknown 37.5 mg Oral

Indications

No indication recorded.